医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Jack Ma Foundation and Alibaba Foundation Announce Donations to Four Southeast Asian Countries

2020年03月19日 PM09:58
このエントリーをはてなブックマークに追加


 

HANGZHOU, China

The Jack Ma Foundation and Alibaba Foundation today announced donations of medical supplies to four Southeast Asian countries.

The foundations have been able to reach out to the governments of Malaysia, Indonesia, Thailand and the Philippines and propose the donation of medical supplies. The foundations’ goal is to aid the fight against the COVID-19 virus in these nations, with more support for other neighboring countries to follow.

“We join hands with our Asian neighbors to fight COVID-19,” said the Jack Ma Foundation when announcing the donation to the four countries. “We and Alibaba Foundation will send 2 million masks, 150,000 test kits, 20,000 protective suits and 20,000 face shields to Indonesia, Malaysia, the Philippines and Thailand. More help to other Asian nations is on the way! Go Asia!”

The foundation donations follow Wednesday’s release of a digital handbook they supported. It shares key lessons and experience from doctors and other medical administrators and staff at a Chinese hospital at the frontline of COVID-19 treatment and crucial to slowing its spread.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200319005410/en/

CONTACT

Rico Ngai (Southeast Asia)

Alibaba Group

+852 9725 9600

rico.ngai@alibaba-inc.com

Adam Najberg (International)

Alibaba Group

+852 5474 3262

adam.najberg@alibaba-inc.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • スミス・ディテクションのBioFlashが空中のCOVID-19を検出可能であることを実証
  • Korean Pet Care Robot PEDDY Gains Popularity to Relieve Pets’ Depression During COVID-19
  • コロナ禍で生じたうつ病をいやす韓国産ペットケアロボット「ペディ」が人気
  • Dr. Reddy’s Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
  • Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists